Scarica l'app Stockscreener
6.205
12.23%
-0.865
Dopo l'orario di chiusura:
6.19
-0.015
-0.24%
Precedente Chiudi:
$7.07
Aprire:
$7.17
Volume 24 ore:
2.05M
Relative Volume:
2.54
Capitalizzazione di mercato:
$326.98M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-6.7446
EPS:
-0.92
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
+0.89%
1M Prestazione:
+47.39%
6M Prestazione:
+164.04%
1 anno Prestazione:
+204.17%
Intervallo 1D:
$6.05
$7.17
Intervallo di 1 settimana:
$6.05
$7.73
Portata 52W:
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
Nome
Immix Biopharma Inc
Settore
Industria
Telefono
(888) 958-1084
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Confronta IMMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
6.205 | 372.56M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sahm
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com
Immix Biopharma — Promising NEXICART-2 data; runway extended - Smartkarma
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley - TipRanks
Form 424B5 Immix Biopharma, Inc. - StreetInsider
Immix Biopharma’s Market Dynamics Amid Economic Shifts - timothysykes.com
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq
Immix Biopharma Prices $100 Million Offering - marketscreener.com
Immix Biopharma Announces Positive Phase 2 Trial Results - TipRanks
Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc. - StreetInsider
Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView — Track All Markets
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sahm
Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 By Investing.com - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 - Investing.com India
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Investing News Network
Immix Biopharma prices offering of 19.1 million shares at $5.10 per share - marketscreener.com
Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share - TradingView — Track All Markets
Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan
Immix Biopharma (IMMX) reports 75% CR at ASH 2025, plans 2026 NXC-201 BLA - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Is Immix Biopharma Inc (IMMX) positioned for future growth? - Setenews
Immix Biopharma, Inc.'s (NASDAQ:IMMX) market cap rose US$18m last week; retail investors who hold 56% profited and so did insiders - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Trading 4.5% Higher – What’s Next? - Defense World
What analysts say about Immix Biopharma Inc stockSector Rotation Strategies & Our Experts Decode Market Noise for You - earlytimes.in
Immix Biopharma Inc Azioni (IMMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):